Loading company…
PolyProx Therapeutics develops Polyproxin molecules that target abnormal proteins for cancer and neurodegenerative disorders.
Established in 2018 and based in Cambridge, UK, PolyProx Therapeutics Ltd is a biopharmaceutical firm developing Polyproxin molecules. The molecules aim to degrade and remove abnormal proteins to treat cancer and neurodegenerative disorders. The company is at the Seed stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in